Chemotherapy with hydroxyurea (NSC-32065) in renal cell carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D001375:Azaguanine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms; D008175:Lung Neoplasms; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms; D013739:Testosterone / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D013739:Testosterone; D014747:Vinblastine; D008525:Medroxyprogesterone; D001375:Azaguanine; D011241:Prednisone; D006918:Hydroxyurea